[go: up one dir, main page]

MX2011006001A - Utilizacion de la asociacion de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca. - Google Patents

Utilizacion de la asociacion de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca.

Info

Publication number
MX2011006001A
MX2011006001A MX2011006001A MX2011006001A MX2011006001A MX 2011006001 A MX2011006001 A MX 2011006001A MX 2011006001 A MX2011006001 A MX 2011006001A MX 2011006001 A MX2011006001 A MX 2011006001A MX 2011006001 A MX2011006001 A MX 2011006001A
Authority
MX
Mexico
Prior art keywords
heart failure
treatment
inhibitor
association
converting enzyme
Prior art date
Application number
MX2011006001A
Other languages
English (en)
Inventor
Guy Lerebours-Pigeonniere
Marie-Dominique Fratacci
Christian Thuillez
Paulus Mulder
Jean-Paul Vilaine
Luc Feldmann
Jerome Roussel
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42985210&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011006001(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2011006001A publication Critical patent/MX2011006001A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Display Devices Of Pinball Game Machines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Utilización de la asociación de un inhibidor selectivo y específico de la corriente sinusal lf, más particularmente la ivabradina o la N-{[(7S)-3,4-dimetoxibiciclo[4.2.0]octa-1,3,5-trie n-7-iI]metil}-3-(7,8-dimetoxi-1,2,4,5-tetrahidro-3H-3-benzazepin- 3-il)-N-metil-3-oxo-1-propanamina y de un agente inhibidor de la enzima de conversión de la angiotensina para la obtención de medicamentos destinados al tratamiento de la insuficiencia cardiaca, más particularmente de la insuficiencia cardiaca con función sistólica conservada.
MX2011006001A 2010-06-15 2011-06-07 Utilizacion de la asociacion de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca. MX2011006001A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1002525A FR2961105B1 (fr) 2010-06-15 2010-06-15 Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque

Publications (1)

Publication Number Publication Date
MX2011006001A true MX2011006001A (es) 2011-12-14

Family

ID=42985210

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011006001A MX2011006001A (es) 2010-06-15 2011-06-07 Utilizacion de la asociacion de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca.

Country Status (47)

Country Link
US (1) US20110306598A1 (es)
EP (2) EP2921168B1 (es)
JP (1) JP5480202B2 (es)
KR (1) KR101389879B1 (es)
CN (2) CN104906579A (es)
AP (2) AP3691A (es)
AR (1) AR081875A1 (es)
AU (1) AU2011202607B2 (es)
BR (1) BRPI1102830F1 (es)
CA (1) CA2743527C (es)
CL (1) CL2011001420A1 (es)
CO (1) CO6640265A2 (es)
CR (1) CR20120609U (es)
CU (1) CU24161B1 (es)
CY (2) CY1116438T1 (es)
DK (2) DK2404600T3 (es)
EA (1) EA022612B1 (es)
EC (1) ECSP12012337A (es)
ES (2) ES2582157T3 (es)
FR (1) FR2961105B1 (es)
GE (1) GEP20146132B (es)
GT (1) GT201200341A (es)
HK (1) HK1210012A1 (es)
HR (2) HRP20150745T1 (es)
HU (2) HUE027088T2 (es)
IL (1) IL223293A (es)
JO (1) JO3309B1 (es)
MA (1) MA33235B1 (es)
ME (2) ME02476B (es)
MX (1) MX2011006001A (es)
MY (1) MY179034A (es)
NI (1) NI201200182A (es)
NZ (2) NZ593437A (es)
PE (1) PE20120019A1 (es)
PH (1) PH12012502315B1 (es)
PL (2) PL2404600T3 (es)
PT (1) PT2404600E (es)
RS (2) RS54838B1 (es)
SA (2) SA114360089B1 (es)
SG (2) SG177069A1 (es)
SI (2) SI2921168T1 (es)
TN (1) TN2012000551A1 (es)
TW (1) TWI468164B (es)
UA (1) UA108983C2 (es)
UY (1) UY33423A (es)
WO (1) WO2011157908A1 (es)
ZA (1) ZA201104222B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603666A (zh) * 2012-02-28 2012-07-25 石河子大学 肉桂酰牛磺酰噻唑烷酸类化合物及其应用
FR3020810B1 (fr) * 2014-05-06 2016-05-06 Servier Lab Nouveau sel de l'ivabradine et son procede de preparation.
EP3025705B8 (en) * 2014-11-25 2018-11-28 Sanofi Ilaç Sanayi ve Ticaret Anonim Sirketi Stable ivabradine formulations
PH12018502155B1 (en) 2016-04-20 2024-03-27 Servier Lab Pharmaceutical composition comprising a beta blocker, a converting enzyme inhibitor and an antihypertensive or an nsaid
KR20190001340A (ko) * 2017-06-27 2019-01-04 에리슨제약(주) 이바브라딘을 포함하는 서방성 약제학적 조성물 및 이의 제조방법
CN107714702A (zh) * 2017-10-31 2018-02-23 泰州中国医药城中医药研究院 一种伊伐布雷定和米力农组合物及其在制药中的应用
CN107550915A (zh) * 2017-10-31 2018-01-09 泰州中国医药城中医药研究院 一种伊伐布雷定和咯利普兰组合物及其在制药中的应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2681862B1 (fr) 1991-09-27 1993-11-12 Adir Cie Nouvelles (benzocycloalkyl)alkylamines, leur procede de preparation, et les compositions pharmaceutiques qui les contiennent.
US6188743B1 (en) * 1997-10-10 2001-02-13 Analogic Corporation Computed tomography scanner drive system and bearing
FR2807431B1 (fr) * 2000-04-06 2002-07-19 Adir Nouveau procede de synthese du perindopril et de ses sels pharmaceutiquement acceptables
DE10018401A1 (de) * 2000-04-13 2001-10-25 Boehringer Ingelheim Pharma Verwendung von Bradycardica bei der Behandlung von mit Hypertrophie einhergehenden Myocarderkrankungen und neue Arzneimittelkombinationen
FR2838648B1 (fr) * 2002-04-18 2004-05-21 Servier Lab Nouveau sel de perindopril et les compositions pharmaceutiques qui le contiennent
ES2211846T3 (es) * 2002-07-25 2004-07-16 BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG Uso de cilobradina o sus sales farmaceuticamente aceptables para el tratamiento o la prevencion de la insuficiencia cardiaca.
EP1799199B1 (en) * 2004-10-08 2012-03-28 Novartis AG Use of renin inhibitors for the prevention or treatment of diastolic dysfunction or diastolic heart failure
WO2007014051A2 (en) * 2005-07-22 2007-02-01 Amylin Pharmaceuticals, Inc. Use of amylin and amylin agonists as cardioprotective or myoprotective agents
FR2891826B1 (fr) * 2005-10-11 2007-12-28 Servier Lab Forme cristalline 6 du chlorhydrate de l'ivabradine, son procede de preparation et les compositions pharmaceutiques qui la contiennent
FR2894825B1 (fr) 2005-12-21 2010-12-03 Servier Lab Nouvelle association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion et les compositions pharmaceutiques qui la contiennent
FR2911279B1 (fr) * 2007-01-11 2009-03-06 Servier Lab Utilisation de l'ivabradine pour l'obtention de medicaments destines au traitement de la dysfonction endotheliale
FR2920773B1 (fr) * 2007-09-11 2009-10-23 Servier Lab Derives de 1,2,4,5-tetrahydro-3h-benzazepines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2921365B1 (fr) * 2007-09-21 2012-10-12 Servier Lab Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2927538B1 (fr) * 2008-02-14 2010-02-19 Servier Lab Association d'un inhibiteur du courant if sinusal et d'un beta-bloquant.
RU2364401C1 (ru) * 2008-05-12 2009-08-20 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции сосудистого ремоделирования у больных хронической сердечной недостаточностью ишемической этиологии
WO2009158005A1 (en) * 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Benzazepinone compounds
RU2382644C1 (ru) * 2008-11-05 2010-02-27 Государственное образовательное учреждение высшего профессионального образования "Пермская государственная медицинская академия имени академика Е.А. Вагнера Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипертрофии левого желудочка у больных ибс в сочетании с гипертонической болезнью

Also Published As

Publication number Publication date
BRPI1102830F1 (pt) 2022-03-29
AR081875A1 (es) 2012-10-24
CA2743527A1 (fr) 2011-12-15
CR20120609U (es) 2013-02-05
JP2012001545A (ja) 2012-01-05
HK1210011A1 (zh) 2016-04-15
SA111320527B1 (ar) 2015-03-19
ES2582157T3 (es) 2016-09-09
TN2012000551A1 (fr) 2014-04-01
MA33235B1 (fr) 2012-05-02
PL2921168T3 (pl) 2016-10-31
EP2921168B1 (fr) 2016-04-13
TW201206445A (en) 2012-02-16
AP3691A (en) 2016-04-30
UY33423A (es) 2011-12-30
PT2404600E (pt) 2015-07-13
AP2013006661A0 (en) 2013-01-31
IL223293A (en) 2017-04-30
ME02476B (me) 2017-02-20
AP2016009002A0 (en) 2016-01-31
BRPI1102830B8 (pt) 2020-01-07
JP5480202B2 (ja) 2014-04-23
SG10201500502WA (en) 2015-03-30
PE20120019A1 (es) 2012-02-11
NI201200182A (es) 2013-05-13
RS54077B1 (sr) 2015-10-30
US20110306598A1 (en) 2011-12-15
HK1210012A1 (en) 2016-04-15
GEP20146132B (en) 2014-08-11
WO2011157908A8 (fr) 2013-01-17
ES2545343T3 (es) 2015-09-10
AU2011202607B2 (en) 2015-02-12
ZA201104222B (en) 2012-02-29
HRP20160643T1 (hr) 2016-07-01
CN104906579A (zh) 2015-09-16
KR20110136752A (ko) 2011-12-21
NZ600931A (en) 2013-04-26
PH12012502315A1 (en) 2013-02-04
CU24161B1 (es) 2016-03-31
EP2921168A1 (fr) 2015-09-23
HUE027788T2 (en) 2016-10-28
BRPI1102830B1 (pt) 2019-10-08
RS54838B1 (sr) 2016-10-31
ECSP12012337A (es) 2012-12-28
DK2921168T3 (en) 2016-08-01
HUE027088T2 (en) 2016-08-29
HRP20150745T1 (hr) 2015-08-14
KR101389879B1 (ko) 2014-04-29
WO2011157908A1 (fr) 2011-12-22
CY1117724T1 (el) 2017-05-17
JO3309B1 (ar) 2018-09-16
DK2404600T3 (en) 2015-08-31
BRPI1102830A2 (pt) 2013-12-24
CN102284060A (zh) 2011-12-21
NZ593437A (en) 2012-08-31
SA114360089B1 (ar) 2016-02-03
PH12012502315B1 (en) 2020-09-18
CA2743527C (fr) 2016-08-02
FR2961105A1 (fr) 2011-12-16
CL2011001420A1 (es) 2012-07-06
EP2404600A1 (fr) 2012-01-11
FR2961105B1 (fr) 2013-02-08
SI2404600T1 (sl) 2015-10-30
AU2011202607A1 (en) 2012-01-12
SG177069A1 (en) 2012-01-30
CU20120166A7 (es) 2013-04-19
ME02163B (me) 2015-10-20
EP2404600B1 (fr) 2015-05-27
IL223293A0 (en) 2013-02-03
EA201100773A1 (ru) 2011-12-30
CO6640265A2 (es) 2013-03-22
CY1116438T1 (el) 2017-02-08
SI2921168T1 (sl) 2016-08-31
TWI468164B (zh) 2015-01-11
UA108983C2 (en) 2015-07-10
EA022612B1 (ru) 2016-02-29
GT201200341A (es) 2014-03-14
PL2404600T3 (pl) 2015-10-30
MY179034A (en) 2020-10-26

Similar Documents

Publication Publication Date Title
MX2011006001A (es) Utilizacion de la asociacion de un inhibidor de la corriente sinusal if y de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca.
WO2011061330A3 (de) Verwendung physiologischer kühlwirkstoffe und mittel enthaltend solche wirkstoffe
MX2011009482A (es) Metodo o sistema que usa biomarcadores para el monitoreo de un tratamiento.
WO2008140708A8 (en) Use of hdac inhibitors for treatment of cardiac rhythm disorders
MX346039B (es) Solucion farmaceutica bebible de telmisartan.
SG133545A1 (en) New association of a sinus node lf current inhibitor and an angiotensin converting enzyme inhibitor, and pharmaceutical compositions containing it
PT2687506E (pt) Processo de síntese enzimática da (7s)-1-(3,4- dimetoxi-biciclo[4.2.0]octa-1,3,5-trieno-7-il)-nmetil- metanamina e aplicação à síntese da ivabradina e dos seus sais
SG133546A1 (en) New association of a sinus node if current inhibitor and a calcium inhibitor, and pharmaceutical compositions containing it
PL2626428T3 (pl) Sposób syntezy enzymatycznej kwasu (7S)-3,4-dimetoksybicyklo[4.2.0]okta-1,3,5-trien-7-karboksylowego lub jego estrów i zastosowania do syntezy iwabradyny i jej soli
WO2007041388A3 (en) Prevention and treatment of hearing disorders
CR11094A (es) Uso de ivabradina como agente de diagnostico en el metodo de angiografia cooronaria mediante tomografia computarizada multicorte
TH137164A (th) การใช้ประโยชน์จากการร่วมกันของสารยับยั้งกระแสไซนัสโหนด If (sinus node If current inhibitor) และสารยับยั้งเอนไซม์ซึ่งเปลี่ยนผันแองจิโอเทนซิน (angiotensin-converting enzyme inhibitor) ในการบำบัดภาวะหัวใจล้มเหลว
MX2009003254A (es) Nuevos derivados de 5-tioxilopiranosa.
PL369984A1 (pl) Nowy szczep bakterii Carnobacterium divergens. Biopreparaty do zwalczania bakterii, zwłaszcza z rodzaju Listeria. Środek dezynfekcyjny do zwalczania bakterii, zwłaszcza z rodzaju Listeria
UA66456C2 (uk) Лікарський засіб кардіологічної дії
HK1185812A (en) Pharmaceutical compositions for terminating acute episodes of cardiac arrhythmia, restoring sinus rhythm, preventing recurrence of cardiac arrhythmia and/or maintaining normal sinus rhythm in mammals
UA107786C2 (ru) Способ оценки эффективности лечения s-амплодипина больных ишемической болезнью сердца с стенокардией и артериальной гипертензией с нарушением диастолической функции левого желудочка по "гипертрофическом" типа

Legal Events

Date Code Title Description
FG Grant or registration